# New Phase 1/2 clinical trials: 2,199 posted since Nov 2024

Updated November 9, 2026.

2,199 clinical studies in phase 1/2 were first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026; 1,084 have an industry sponsor and 1,830 are recruiting or about to. The newest, NCT07926607, was posted on November 9, 2026: Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia (Second Affiliated Hospital of Nanchang University).

## The full list

New Phase 1/2 clinical trials: 2,199 rows for $101.99, first posted on ClinicalTrials.gov from November 12, 2024 to November 9, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Enrollment, Enrollment type, Location countries, Central contact, Contact phone, Contact email, Last update posted, Read on, Source. The new rows each week by email, about 82 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (central contact, contact phone, contact email, sponsor class, condition groups (MeSH), interventions and 5 more), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/phase/phase-1-2

SpecStream is the live web data engine for teams and agents. It reads every new study on ClinicalTrials.gov each morning, and this page is that reading. Ask for the conditions, phases or countries you follow and each new trial arrives in your sheet, CRM, Slack or agent with the sponsor, the sites and the listed contact.

- New trials: 2,199
- Industry sponsored: 1,084
- Recruiting or not yet: 1,830
- Latest posted: November 9, 2026

## Newest trials

The newest 100 of 2,199, each linked to its record. The full list holds every one with the sponsor class, interventions, start date and the central contact as the record prints it.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Countries | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 9, 2026 | NCT07926607 | Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Second Affiliated Hospital of Nanchang University | Phase 1/2 | Not yet recruiting | Acute Myeloblastic Leukemia | 55 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926607) |
| November 9, 2026 | NCT07925801 | Relacorilant in Patients With Poorly Controlled Type 2 Diabetes and Autonomous Cortisol Secretion | The University of Texas Health Science Center at San Antonio | Phase 1/2 | Not yet recruiting | Type 2 Diabetes, Hypercortisolism | 34 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07925801) |
| November 6, 2026 | NCT07923838 | Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease | Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Active not recruiting | Parkinson Disease (PD) | 9 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923838) |
| November 6, 2026 | NCT07923045 | A Phase 1/2, Single-Dose, Multicenter, Dose Escalation, Clinical Trial to Evaluate the Safety and Efficacy of MR-146: An Open-Label Part 1... | Viatris Inc. | Phase 1/2 | Recruiting | Neurotrophic Keratopathy | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07923045) |
| November 6, 2026 | NCT07922889 | Mesenchymal Stem Cell Exosomes Alone or Combined With HUVEC Exosomes in Non-Dialysis Chronic Kidney Disease | Nurhasan Agung Prabowo | Phase 1/2 | Completed | Chronic Kidney Disease Stage 3, Chronic Kidney Disease Stage 4, Chronic Kidney Disease | 34 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922889) |
| November 6, 2026 | NCT07921576 | Phase 1/2 Study of DS010 in Advanced Cancer Patients With Cachexia | Dartsbio Pharmaceuticals Ltd. | Phase 1/2 | Recruiting | Cancer, Cachexia | 58 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07921576) |
| November 5, 2026 | NCT07920289 | Intravenously Administered PROMITIL Combined With Radiotherapy in Patients With Cisplatin-Ineligible Head and Neck Cancer Patients | Assuta Ashdod Hospital | Phase 1/2 | Not yet recruiting | Head & Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma | 20 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920289) |
| November 5, 2026 | NCT07920172 | Clinical Trial of Recombinant Herpes Zoster Vaccine (ZFA01 Adjuvant, CHO Cells) | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | Phase 1/2 | Recruiting | Herpes Zoster | 500 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920172) |
| November 5, 2026 | NCT07920081 | Psilocybin for Amblyopia - Targeting Critical Periods in Humans | Johns Hopkins University | Phase 1/2 | Recruiting | Amblyopia | 24 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920081) |
| November 5, 2026 | NCT07918261 | Evaluation of Fisetin to Reduce Systemic Senescence | Steadman Philippon Research Institute | Phase 1/2 | Completed | Cellular Senescence | 82 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918261) |
| November 4, 2026 | NCT07917390 | ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The... | University of Florida | Phase 1/2 | Not yet recruiting | Prostate Cancer Metastatic to Bone | 42 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917390) |
| November 4, 2026 | NCT07915921 | A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic... | Genfleet Therapeutics (Shanghai) Inc. | Phase 1/2 | Not yet recruiting | CRC | 150 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915921) |
| November 3, 2026 | NCT07913347 | Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study) | Metagen Therapeutics, Inc. | Phase 1/2 | Recruiting | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | 54 | Japan, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913347) |
| November 3, 2026 | NCT07912593 | Phase 1/2, Open-label Study of ETX-929, a KRAS Inhibitor in Participants With Advanced Solid Tumors | Ensem Therapeutics | Phase 1/2 | Recruiting | Metastatic Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Non-squamous, Non-Small Cell Lung Cancer... | 320 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912593) |
| November 3, 2026 | NCT07912463 | Phase Ib/II Trial of Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer | Xuelei Ma MD | Phase 1/2 | Not yet recruiting | Locally Advanced Rectal Cancer | 126 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912463) |
| November 3, 2026 | NCT07912346 | Arginine-Restricted Diet Combined With Chemoradiotherapy in Neoadjuvant Rectal Cancer: A Phase Ib/II Trial | Xuelei Ma MD | Phase 1/2 | Not yet recruiting | Rectal Cancer Patients | 126 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912346) |
| November 3, 2026 | NCT07911748 | A Study of MBS314 for Injection in Participants With Relapsed/Refractory Multiple Myeloma. | Beijing Mabworks Biotech Co., Ltd. | Phase 1/2 | Not yet recruiting | Multiple Myeloma | 78 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911748) |
| November 3, 2026 | NCT07911579 | A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid Tumors | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 154 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07911579) |
| November 2, 2026 | NCT07910526 | Umbilical Cord Mesenchymal Stem Cell Secretome in Patients With Sjogren's Syndrome | Universitas Sebelas Maret Hospital | Phase 1/2 | Completed | Sjogren's Syndrome | 29 | Indonesia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07910526) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| November 2, 2026 | NCT07908524 | MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) | Merck Sharp & Dohme LLC | Phase 1/2 | Not yet recruiting | Metastatic Castration-resistant Prostate Cancer | 290 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908524) |
| October 30, 2026 | NCT07907588 | Effect of Bee Venom on T Regulatory Cells and Inflammation in Hemodialysis Patients: a Prospective Study Thesis | Mansoura University | Phase 1/2 | Completed | Hemodialysis, Inflammation, Regulatory T Cell | 60 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907588) |
| October 30, 2026 | NCT07906925 | Effect of Temperature Elevation on the Antimicrobial Efficacy of Two Root Canal Irrigants in Primary Root Canal Infections: A Randomized... | Tanta University | Phase 1/2 | Not yet recruiting | Irreversible Pulpitis | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906925) |
| October 29, 2026 | NCT07905261 | Clinical Study of SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd | Phase 1/2 | Not yet recruiting | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | 384 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905261) |
| October 29, 2026 | NCT07905131 | A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic Cancer | Daniel Nussbaum, M.D. | Phase 1/2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC) | 18 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905131) |
| October 29, 2026 | NCT07905105 | A Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction | Cytogel Pharma, LLC | Phase 1/2 | Recruiting | Acute Postoperative Pain, Dental Pain | 32 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07905105) |
| October 29, 2026 | NCT07902921 | STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic... | National Cancer Institute (NCI) | Phase 1/2 | Not yet recruiting | NSCLC, Non-Small Cell Lung Cancer, Lung Cancer, Prostate Cancer, Thymic Epithelial Tumors, TETs, Thymic Carcinomas... | 67 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902921) |
| October 28, 2026 | NCT07902037 | A Study of SRN-101 Gene Therapy in Adults With Recurrent High-Grade Glioma (ALERT-1) | Siren Biotechnology | Phase 1/2 | Not yet recruiting | Recurrent High Grade Gliomas, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Diffuse Hemispheric Glioma | 40 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902037) |
| October 28, 2026 | NCT07901595 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PAL-119 in Healthy Volunteers and Adult Participants With Type 1 or Type 2... | Paulex Bio Inc. | Phase 1/2 | Not yet recruiting | Healthy Volunteers and Diabetes Participants | 147 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901595) |
| October 28, 2026 | NCT07901413 | Evaluation of ICP-B381 in Patients With Advanced Solid Tumors | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor | 348 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901413) |
| October 28, 2026 | NCT07901309 | Efficacy and Safety of Dapagliflozin as an Adjunct to Conventional Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid... | Tanta University | Phase 1/2 | Not yet recruiting | Rheumatoid Arthritis (RA | 100 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901309) |
| October 28, 2026 | NCT07900165 | Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer | CytomX Therapeutics | Phase 1/2 | Not yet recruiting | Colo-rectal Cancer | 368 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900165) |
| October 28, 2026 | NCT07899996 | A Study of HB0056 in Adult Participants With Moderate to Severe Asthma | Shanghai Huaota Biopharmaceutical Co., Ltd. | Phase 1/2 | Recruiting | Asthma | 160 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899996) |
| October 28, 2026 | NCT07899983 | Effect of Povidone Iodine on the Dental Implant Internal Surface Microbiome | Madigan Army Medical Center | Phase 1/2 | Not yet recruiting | Dental Implant | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899983) |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| October 27, 2026 | NCT07897981 | High-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver Disease | Li Lab,MD | Phase 1/2 | Recruiting | Alcohol-associated Fatty Liver Disease | 74 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897981) |
| October 27, 2026 | NCT07897734 | TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and... | Tango Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC, RAS Mutation, MTAP Deletion, Lung Cancer, Pancreatic Cancer... | 188 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897734) |
| October 27, 2026 | NCT07897448 | A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | Phase 1/2 | Not yet recruiting | Chronic Hepatitis B | 105 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897448) |
| October 27, 2026 | NCT07897383 | Investigating the Effects of 24 Hour LEAP2 Infusion in Individuals With Overweight and Obesity | University Hospital, Gentofte, Copenhagen | Phase 1/2 | Not yet recruiting | Obesity & Overweight | 18 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897383) |
| October 27, 2026 | NCT07897227 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SYS6062 in Patients With Advanced Solid Tumors. | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Gastric Cancer (GC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC) | 260 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07897227) |
| October 27, 2026 | NCT07896941 | Safety and Efficacy of CG-BM1 in Ischemic Stroke | GuangZhou Cellgenes Biotechnology Co., Ltd. | Phase 1/2 | Recruiting | Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) | 87 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896941) |
| October 26, 2026 | NCT07894887 | EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C) | Editas Medicine, Inc. | Phase 1/2 | Not yet recruiting | Heterozygous Familial Hypercholesterolemia (HeFH) | 56 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07894887) |
| October 23, 2026 | NCT07893288 | A Study of Single and Combination Lipase Dietary Supplements to Increase Fatty Acid Absorption in Generally Health Adults | Danisco | Phase 1/2 | Not yet recruiting | Digestive Symptoms, Gastrointestinal Symptoms, Healthy, Impaired Pancreatic Function | 50 | Canada | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893288) |
| October 23, 2026 | NCT07893171 | Study of CM529D1 in Participants With Advanced Solid Tumors | Keymed Biosciences Co.Ltd | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 128 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893171) |
| October 23, 2026 | NCT07892989 | Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Herpes Zoster | 496 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07892989) |
| October 23, 2026 | NCT07891104 | A Phase I/II Clinical Trial of the Diphtheria, Tetanus, Acellular Component Pertussis and Sabin Inactivated Poliomyelitis Vaccine Adsorbed | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1/2 | Recruiting | Diphtheria, Pertussis, Tetanus, Poliomyelitis, Diphtheria-Tetanus-aPertussis-Poliomyelitis Vaccines | 380 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07891104) |
| October 22, 2026 | NCT07890714 | A Study of Dato-DXd in Participants With Solid Tumors \[TROPION-PanTumor04 (TP04)\] | Daiichi Sankyo | Phase 1/2 | Recruiting | Urothelial Cancer, Non-small Cell Lung Cancer | 268 | Taiwan | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890714) |
| October 22, 2026 | NCT07890701 | A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent... | Second Affiliated Hospital of Wenzhou Medical University | Phase 1/2 | Enrolling by invitation | Histiocytosis,Langerhans-Cell | 2 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890701) |
| October 22, 2026 | NCT07890025 | CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study | Hospital Universitario Dr. Jose E. Gonzalez | Phase 1/2 | Not yet recruiting | Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | 30 | Mexico | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890025) |
| October 22, 2026 | NCT07889232 | Tocilizumab Combined With First-Line Chemo-Immunotherapy in Metastatic Non-Small Cell Lung Cancer | VA Office of Research and Development | Phase 1/2 | Not yet recruiting | Metastatic Non-Small Cell Lung Cancer, Cancer-Associated Weight Loss, Elevated Inflammatory Markers | 43 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07889232) |
| October 22, 2026 | NCT07888686 | Clinical Trial to Assess the Safety, Tolerability, Reactogenicity, and Immunogenicity of a 10 Valent Human Papillomavirus Virus (10vHPV)... | Serum Institute of India Pvt. Ltd. | Phase 1/2 | Not yet recruiting | Human Papillomavirus Infection | 72 | Australia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888686) |
| October 22, 2026 | NCT07888348 | Anakinra for Prevention of Poor Graft Function in MDS Allo-HSCT | Ruijin Hospital | Phase 1/2 | Not yet recruiting | Poor Graft Function, Myelodysplastic Syndromes, Hematopoietic Stem Cell Transplantation | 66 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888348) |
| October 21, 2026 | NCT07887750 | REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs) | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Diffuse Large B-Cell Lymphoma (DLBCL) | 36 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887750) |
| October 21, 2026 | NCT07887347 | A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency | Prime Medicine, Inc. | Phase 1/2 | Not yet recruiting | Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease, Alpha-1 Antitrypsin Deficiency... | 54 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07887347) |
| October 21, 2026 | NCT07886684 | A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known... | BioNTech SE | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 173 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886684) |
| October 21, 2026 | NCT07885683 | MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) | Imagion Biosystems, Inc. | Phase 1/2 | Not yet recruiting | HER2-positive Breast Cancer | 70 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885683) |
| October 21, 2026 | NCT07885397 | Sonrotoclax Plus Azacitidine in Patients With MDS-IB2 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Phase 1/2 | Recruiting | Myelodysplastic Syndromes, High Risk | 60 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885397) |
| October 21, 2026 | NCT07885319 | Efficacy and Safety of Ivonescimab Plus Pemetrexed and Platinum-Based Chemotherapy in Advanced Malignant Pleural Mesothelioma | Ruijin Hospital | Phase 1/2 | Recruiting | Malignant Pleural Mesothelioma, Advanced | 78 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885319) |
| October 21, 2026 | NCT07885228 | Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease | Nanfang Hospital, Southern Medical University | Phase 1/2 | Not yet recruiting | Acute Graft vs Host Disease | 49 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07885228) |
| October 20, 2026 | NCT07883382 | An Exploratory Study on the Use of Gecacitinib in Patients With Myeloid Malignancies and Myelofibrosis During the Peri-transplant Period... | Ruijin Hospital | Phase 1/2 | Recruiting | Myeloid Neoplasms With Myelofibrosis | 10 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07883382) |
| October 20, 2026 | NCT07882641 | BEX101 in B-cell Non-Hodgkin's Lymphoma | Chinese PLA General Hospital | Phase 1/2 | Recruiting | Non-Hodgkin's Lymphoma | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07882641) |
| October 19, 2026 | NCT07880873 | Defibrio AED Study | Defibrio, LLC | Phase 1/2 | Not yet recruiting | VF, VT | 25 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07880873) |
| October 16, 2026 | NCT07879495 | Alveolar Ridge Preservation (ARP) Study Using Alloplastic Biomaterial and a Resorbable Synthetic Membrane. A Digital Workflow... | Universidad Católica San Antonio de Murcia | Phase 1/2 | Not yet recruiting | Alveolar Ridge Augmentation, Bone Substitutes, Guided Tissue Regeneration, Periodontal, Cone-Beam Computed Tomography... | 28 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07879495) |
| October 16, 2026 | NCT07878689 | Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma | University of Texas Southwestern Medical Center | Phase 1/2 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 36 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878689) |
| October 16, 2026 | NCT07877701 | Acute Nicotine Gum and Auditory Brain Responses in Adults With Chronic Tinnitus | San Diego State University | Phase 1/2 | Not yet recruiting | Tinnitus, Chronic Subjective Tinnitus | 20 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877701) |
| October 16, 2026 | NCT07877610 | CARCIK CD123/33 for Refractory/Relapsed AML and BPDCN in Children and Adults | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Phase 1/2 | Recruiting | AML (Acute Myeloid Leukemia), BPDCN | 18 | Italy | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07877610) |
| October 15, 2026 | NCT07876856 | A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) | Ausper Biopharma Co., Ltd. | Phase 1/2 | Not yet recruiting | Chronic Hepatitis B | 105 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876856) |
| October 15, 2026 | NCT07876804 | A Long-term Follow-up Study in Male Participants With X-linked Myotubular Myopathy Treated With ASP2957 | Astellas Gene Therapies | Phase 1/2 | Not yet recruiting | X-linked Myotubular Myopathy | 9 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876804) |
| October 15, 2026 | NCT07876128 | A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) | Merck Sharp & Dohme LLC | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Malignant Neoplasm | 300 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07876128) |
| October 14, 2026 | NCT07874347 | Home-Based Outpatient Model for BCG Delivery to Reduce Undue Burden on Patients Undergoing Treatment for Non-Muscle Invasive Bladder... | Ohio State University Comprehensive Cancer Center | Phase 1/2 | Not yet recruiting | Non-Muscle Invasive Bladder Carcinoma | 49 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874347) |
| October 14, 2026 | NCT07873827 | KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies | Stemline Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | Hematological Malignancy | 115 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873827) |
| October 14, 2026 | NCT07873450 | SumMET: Study of \[225Ac\]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET | Full-Life Technologies UK Limited | Phase 1/2 | Recruiting | Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer, Cholangiocarcinoma | 208 | Australia, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07873450) |
| October 13, 2026 | NCT07871890 | A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease | SMSbiotech | Phase 1/2 | Not yet recruiting | Chronic Obstructive Lung Disease | 125 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871890) |
| October 13, 2026 | NCT07871877 | Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder | Clive Michelsen | Phase 1/2 | Not yet recruiting | Opioid Use Disorder, Opioid Withdrawal, Substance Use Disorders | 60 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871877) |
| October 13, 2026 | NCT07871435 | GI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)... | GI Innovation, Inc. | Phase 1/2 | Recruiting | Metastatic Castration-resistant Prostate Cancer (mCRPC) | 107 | South Korea, United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871435) |
| October 13, 2026 | NCT07871006 | Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1 | Xijing Hospital | Phase 1/2 | Recruiting | Narcolepsy Type 1 (NT1) | 20 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871006) |
| October 13, 2026 | NCT07870447 | Preoperative Celecoxib and Acetaminophen Versus Acetaminophen Alone for Pain Control After Pediatric Adenotonsillectomy | NYU Langone Health | Phase 1/2 | Not yet recruiting | Adenotonsillectomy, Postoperative Pain | 500 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870447) |
| October 13, 2026 | NCT07869953 | Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis | BioNanoSim Ltd. | Phase 1/2 | Completed | Non-Infectious Anterior Uveitis | 18 | Israel | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07869953) |
| October 9, 2026 | NCT07868172 | GST101 in Participants With RAS-Mutant Advanced Solid Tumors | Genuine Seed Therapeutics (Zhuhai) Co., Ltd. | Phase 1/2 | Recruiting | RAS-mutant Advanced Solid Tumors | 172 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868172) |
| October 8, 2026 | NCT07865780 | Photobiomodulation Alone Versus Photobiomodulation Combined With Topical Oral Oxygen Therapy for Radiotherapy-Induced Oral Mucositis in... | Assiut University | Phase 1/2 | Enrolling by invitation | Mucositis Oral, Head & Neck Cancer | 46 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865780) |
| October 8, 2026 | NCT07865676 | Clinical Trial of CG-BM1 Allogeneic Human Bone Marrow Mesenchymal Stem Cell Injection in the Treatment of Sarcopenia | GuangZhou Cellgenes Biotechnology Co., Ltd. | Phase 1/2 | Recruiting | Sarcopenia | 30 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865676) |
| October 8, 2026 | NCT07864701 | Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers | Chengdu Anticancer Bioscience, Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Lymphoma, Non-Hodgkin | 150 | China | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864701) |
| October 8, 2026 | NCT07864584 | Study Using a Drug-device Combination Product to Determine Safety, Tolerability and Antitumor Activity for Patients With Advanced... | Nob Hill Therapeutics, Inc. | Phase 1/2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864584) |
| October 7, 2026 | NCT07864207 | Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic) | IDP Discovery Pharma S.L. | Phase 1/2 | Recruiting | Small Cell Lung Cancer ( SCLC ) | 60 | Spain | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864207) |
| October 7, 2026 | NCT07864181 | TheraCal PT vs. Formocresol in Primary Molar Pulpotomies | Hama University | Phase 1/2 | Completed | Reversible Pulpitis | 50 | Syria | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07864181) |
| October 7, 2026 | NCT07863869 | The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver... | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 1/2 | Not yet recruiting | Colorectal Cancer Metastatic to Liver | 102 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863869) |
| October 7, 2026 | NCT07863180 | Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial | Prabesh Kanel | Phase 1/2 | Recruiting | Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy(PSP) | 15 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863180) |
| October 7, 2026 | NCT07863024 | Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET... | Regeneron Pharmaceuticals | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors | 320 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07863024) |
| October 7, 2026 | NCT07862582 | RYZ711 Diagnostic Platform Study | RayzeBio, Inc. | Phase 1/2 | Not yet recruiting | Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer... | 116 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862582) |
| October 7, 2026 | NCT07862335 | Evaluating Autologous Platelet-Rich Fibrin Plasma for Chronic Lower Extremity Ulcers | Tiger Biosciences, LLC. | Phase 1/2 | Not yet recruiting | Lower Extremity, Chronic Ulcers, Pressure Ulcer (PU), Venous Leg Ulcer (VLU), Wound Management | 30 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862335) |
| October 6, 2026 | NCT07861932 | A Phase 1/2a Study of K-1728 in Advanced Solid Tumors | KymaThera, Inc. | Phase 1/2 | Not yet recruiting | Breast Neoplasms, Solid Tumors, PIK3CA Gene Mutation | 110 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861932) |
| October 5, 2026 | NCT07859358 | Injectable Platelet-Rich Fibrin (i-PRF) and Oxygen-Releasing Gel in the Treatment of Stage II Periodontitis. | Assiut University | Phase 1/2 | Completed | Stage III Periodontitis | 24 | Egypt | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859358) |
| October 5, 2026 | NCT07859059 | Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma | University of Nebraska | Phase 1/2 | Not yet recruiting | High Grade Glioma, Glioblastoma, Gliosarcoma | 41 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859059) |
| October 5, 2026 | NCT07858643 | A Study of LDGraft In Single Level Lumbar Interbody Fusion | Locate Bio Ltd | Phase 1/2 | Recruiting | Degenerative Disc Disease Lumbar | 25 | Georgia | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858643) |
| October 5, 2026 | NCT07857135 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 1/2 | Not yet recruiting | Advanced/Metastatic Solid Tumors | 140 |  | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07857135) |
| October 2, 2026 | NCT07856082 | Opt-IVF for Personalized Medicine for Normal Responders | Urmila DIwekar | Phase 1/2 | Active not recruiting | Ivf | 100 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856082) |
| October 2, 2026 | NCT07855211 | A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS) | Biogen | Phase 1/2 | Recruiting | Amyotrophic Lateral Sclerosis | 69 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855211) |
| October 2, 2026 | NCT07855172 | Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus... | Serum Institute of India Pvt. Ltd. | Phase 1/2 | Not yet recruiting | Diptheria Immunization, Tetanus Immunization, Pertussis Immunization, Hepatitis B Immunization, Haemophilus... | 186 | Bangladesh | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07855172) |
| October 1, 2026 | NCT07853105 | Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With... | University Hospital, Strasbourg, France | Phase 1/2 | Not yet recruiting | Osteosarcomas, Bone Cancer, Ewing Sarcomas | 89 | France | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07853105) |
| October 1, 2026 | NCT07852650 | Digital STEADI Efficacy | Friendi.fi Corporation | Phase 1/2 | Recruiting | Fall, Mild Cognitive Impairment (MCI), Aging | 300 | United States | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07852650) |

## Sponsors posting most

| Sponsor | New trials | Latest |
| --- | --- | --- |
| Beijing Biotech | 28 | August 4, 2026 |
| AstraZeneca | 20 | July 21, 2026 |
| M.D. Anderson Cancer Center | 19 | October 1, 2026 |
| Institute of Hematology & Blood Diseases Hospital, China | 19 | August 11, 2026 |
| Merck Sharp & Dohme LLC | 18 | November 2, 2026 |
| West China Hospital | 17 | September 23, 2026 |
| Peking Union Medical College Hospital | 16 | September 23, 2026 |
| n-Lorem Foundation | 16 | August 3, 2026 |
| GlaxoSmithKline | 16 | June 4, 2026 |
| Ruijin Hospital | 15 | October 22, 2026 |
| Sun Yat-sen University | 14 | May 29, 2026 |
| National Cancer Institute (NCI) | 13 | October 29, 2026 |
| Jiangsu HengRui Medicine Co., Ltd. | 13 | September 8, 2026 |
| Novartis Pharmaceuticals | 13 | May 6, 2026 |
| BioNTech SE | 12 | October 21, 2026 |
| Memorial Sloan Kettering Cancer Center | 12 | September 14, 2026 |
| Qilu Pharmaceutical Co., Ltd. | 12 | July 29, 2026 |
| CSPC Megalith Biopharmaceutical Co.,Ltd. | 11 | October 27, 2026 |
| Regeneron Pharmaceuticals | 11 | October 21, 2026 |
| Sinocelltech Ltd. | 11 | September 14, 2026 |

## Conditions

| Condition group | New trials | Latest |
| --- | --- | --- |
| [Carcinoma, Non-Small-Cell Lung](https://specstream.ai/data/clinical-trials/condition/carcinoma-non-small-cell-lung) | 101 | November 3, 2026 |
| [Colorectal Neoplasms](https://specstream.ai/data/clinical-trials/condition/colorectal-neoplasms) | 77 | November 3, 2026 |
| [Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/breast-neoplasms) | 67 | October 6, 2026 |
| [Recurrence](https://specstream.ai/data/clinical-trials/condition/recurrence) | 62 | November 2, 2026 |
| [Neoplasms](https://specstream.ai/data/clinical-trials/condition/neoplasms) | 59 | November 6, 2026 |
| [Pancreatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/pancreatic-neoplasms) | 59 | October 29, 2026 |
| [Prostatic Neoplasms](https://specstream.ai/data/clinical-trials/condition/prostatic-neoplasms) | 53 | November 4, 2026 |
| [Neoplasm Metastasis](https://specstream.ai/data/clinical-trials/condition/neoplasm-metastasis) | 47 | November 2, 2026 |
| [Ovarian Neoplasms](https://specstream.ai/data/clinical-trials/condition/ovarian-neoplasms) | 46 | November 2, 2026 |
| [Stomach Neoplasms](https://specstream.ai/data/clinical-trials/condition/stomach-neoplasms) | 43 | October 27, 2026 |
| [Multiple Myeloma](https://specstream.ai/data/clinical-trials/condition/multiple-myeloma) | 41 | November 3, 2026 |
| [Leukemia, Myeloid, Acute](https://specstream.ai/data/clinical-trials/condition/leukemia-myeloid-acute) | 36 | November 9, 2026 |
| [Squamous Cell Carcinoma of Head and Neck](https://specstream.ai/data/clinical-trials/condition/squamous-cell-carcinoma-of-head-and-neck) | 36 | November 5, 2026 |
| [Melanoma](https://specstream.ai/data/clinical-trials/condition/melanoma) | 33 | September 25, 2026 |
| [Small Cell Lung Carcinoma](https://specstream.ai/data/clinical-trials/condition/small-cell-lung-carcinoma) | 32 | October 7, 2026 |
| [Carcinoma, Hepatocellular](https://specstream.ai/data/clinical-trials/condition/carcinoma-hepatocellular) | 29 | October 16, 2026 |
| [Glioblastoma](https://specstream.ai/data/clinical-trials/condition/glioblastoma) | 28 | October 28, 2026 |
| [Lung Neoplasms](https://specstream.ai/data/clinical-trials/condition/lung-neoplasms) | 27 | October 29, 2026 |
| [Triple Negative Breast Neoplasms](https://specstream.ai/data/clinical-trials/condition/triple-negative-breast-neoplasms) | 27 | October 27, 2026 |
| [Endometrial Neoplasms](https://specstream.ai/data/clinical-trials/condition/endometrial-neoplasms) | 24 | November 2, 2026 |
| [Lymphoma](https://specstream.ai/data/clinical-trials/condition/lymphoma) | 24 | February 13, 2026 |
| [Obesity](https://specstream.ai/data/clinical-trials/condition/obesity) | 23 | October 27, 2026 |
| [Lymphoma, Large B-Cell, Diffuse](https://specstream.ai/data/clinical-trials/condition/lymphoma-large-b-cell-diffuse) | 21 | October 21, 2026 |
| [Parkinson Disease](https://specstream.ai/data/clinical-trials/condition/parkinson-disease) | 20 | November 6, 2026 |
| Lymphoma, B-Cell | 20 | October 29, 2026 |

## By country

| Country | New trials | Latest |
| --- | --- | --- |
| [China](https://specstream.ai/data/clinical-trials/country/china) | 802 | November 9, 2026 |
| [United States](https://specstream.ai/data/clinical-trials/country/united-states) | 721 | November 9, 2026 |
| [Australia](https://specstream.ai/data/clinical-trials/country/australia) | 154 | November 6, 2026 |
| [Spain](https://specstream.ai/data/clinical-trials/country/spain) | 133 | October 7, 2026 |
| [France](https://specstream.ai/data/clinical-trials/country/france) | 103 | October 1, 2026 |
| [United Kingdom](https://specstream.ai/data/clinical-trials/country/united-kingdom) | 102 | September 16, 2026 |
| [Canada](https://specstream.ai/data/clinical-trials/country/canada) | 93 | October 23, 2026 |
| [South Korea](https://specstream.ai/data/clinical-trials/country/south-korea) | 88 | October 13, 2026 |
| [Italy](https://specstream.ai/data/clinical-trials/country/italy) | 73 | October 16, 2026 |
| [Germany](https://specstream.ai/data/clinical-trials/country/germany) | 73 | September 28, 2026 |
| [Japan](https://specstream.ai/data/clinical-trials/country/japan) | 70 | November 3, 2026 |
| [Egypt](https://specstream.ai/data/clinical-trials/country/egypt) | 50 | October 30, 2026 |
| [Taiwan](https://specstream.ai/data/clinical-trials/country/taiwan) | 49 | October 22, 2026 |
| [Brazil](https://specstream.ai/data/clinical-trials/country/brazil) | 42 | August 25, 2026 |
| [Netherlands](https://specstream.ai/data/clinical-trials/country/netherlands) | 41 | September 28, 2026 |
| [Israel](https://specstream.ai/data/clinical-trials/country/israel) | 36 | October 13, 2026 |
| [Belgium](https://specstream.ai/data/clinical-trials/country/belgium) | 36 | September 28, 2026 |
| [Poland](https://specstream.ai/data/clinical-trials/country/poland) | 32 | September 28, 2026 |
| [Turkey (Türkiye)](https://specstream.ai/data/clinical-trials/country/turkey-t-rkiye) | 25 | July 31, 2026 |
| [New Zealand](https://specstream.ai/data/clinical-trials/country/new-zealand) | 24 | September 21, 2026 |
| [Sweden](https://specstream.ai/data/clinical-trials/country/sweden) | 20 | August 17, 2026 |
| [Denmark](https://specstream.ai/data/clinical-trials/country/denmark) | 20 | June 9, 2026 |
| [Singapore](https://specstream.ai/data/clinical-trials/country/singapore) | 19 | August 26, 2026 |
| [Pakistan](https://specstream.ai/data/clinical-trials/country/pakistan) | 15 | September 8, 2026 |
| [Norway](https://specstream.ai/data/clinical-trials/country/norway) | 15 | May 12, 2026 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Condition groups are the MeSH terms ClinicalTrials.gov assigns to each study's conditions; a study with several is in several groups. Sponsor class is the register's class of the lead sponsor. The central contact is in the full list only as the record prints it.

Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).